Our top pick for
Vascular Biogenics Ltd is a biotechnology business based in the US. Vascular Biogenics shares (VBLT) are listed on the NASDAQ and all prices are listed in US Dollars. Vascular Biogenics employs 38 staff and has a trailing 12-month revenue of around USD$843,000.
|52-week range||USD$0.9 - USD$2.49|
|50-day moving average||USD$1.7705|
|200-day moving average||USD$1.3589|
|Wall St. target price||USD$3.85|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.504|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$399,000|
|Return on assets TTM||-28.55%|
|Return on equity TTM||-57.95%|
|Market capitalisation||USD$116.4 million|
TTM: trailing 12 months
There are currently 659,022 Vascular Biogenics shares held short by investors – that's known as Vascular Biogenics's "short interest". This figure is 61.9% up from 406,981 last month.
There are a few different ways that this level of interest in shorting Vascular Biogenics shares can be evaluated.
Vascular Biogenics's "short interest ratio" (SIR) is the quantity of Vascular Biogenics shares currently shorted divided by the average quantity of Vascular Biogenics shares traded daily (recently around 323050). Vascular Biogenics's SIR currently stands at 2.04. In other words for every 100,000 Vascular Biogenics shares traded daily on the market, roughly 2040 shares are currently held short.
However Vascular Biogenics's short interest can also be evaluated against the total number of Vascular Biogenics shares, or, against the total number of tradable Vascular Biogenics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Vascular Biogenics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Vascular Biogenics shares in existence, roughly 10 shares are currently held short) or 0.0177% of the tradable shares (for every 100,000 tradable Vascular Biogenics shares, roughly 18 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Vascular Biogenics.
Find out more about how you can short Vascular Biogenics stock.
We're not expecting Vascular Biogenics to pay a dividend over the next 12 months.
Over the last 12 months, Vascular Biogenics's shares have ranged in value from as little as $0.9 up to $2.49. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Vascular Biogenics's is 1.1639. This would suggest that Vascular Biogenics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer and immune/inflammatory indications. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. Its lead product candidate is VB-111, a gene-based biologic that is in Phase 3 clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; and in Phase 1/2 clinical trials for recurrent platinum-resistant ovarian cancer, as well as in Phase 2 clinical trials to treat GI tumors and has completed phase 2 clinical trial for the treatment of thyroid cancer. In addition, it is developing VB-511, an anti-angiogenic candidate for oncology; and VB-211 and VB-411, which are pro-angiogenic candidates for the treatment of peripheral vascular diseases. Further, the company is developing VB-201, a Lecinoxoid-based compound used to treat atherosclerosis that has completed phase II clinical, as well as in pre-clinical stage for the treatment of NASH and renal fibrosis. It is also developing VB-601 and 611 for immuno-oncology and anti-inflammatory applications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was founded in 2000 and is headquartered in Modi'in, Israel.
Steps to owning and managing DRIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing CYBR, with 24-hour and historical pricing before you buy.
Steps to owning and managing CHCI, with 24-hour and historical pricing before you buy.
Steps to owning and managing CIGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing CKX, with 24-hour and historical pricing before you buy.
Steps to owning and managing CHA, with 24-hour and historical pricing before you buy.
Steps to owning and managing CTHR, with 24-hour and historical pricing before you buy.
Steps to owning and managing CNBKA, with 24-hour and historical pricing before you buy.
Steps to owning and managing CATM, with 24-hour and historical pricing before you buy.
Steps to owning and managing CRME, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.